Published ahead of print on January 6, 2003, doi:10.1164/rccm.200210-1125OC
American Journal of Respiratory and Critical Care Medicine Vol 167. pp. 1348-1354, (2003)
© 2003 American Thoracic Society
Bactericidal and Sterilizing Activities of Antituberculosis Drugs during the First 14 Days
Amina Jindani,
Caroline J. Doré and
Denis A. Mitchison
Clinical Trials Program, International Union Against Tuberculosis and Lung Disease, Paris, France; Medical Research Council Clinical Trials Unit; and Department of Medical Microbiology, St George's Hospital Medical School, London, United Kingdom
Correspondence and requests for reprints should be addressed to Denis A. Mitchison, M.D., Department of Medical Microbiology, St George's Hospital Medical School, Cranmer Terrace, London SW17 0RE, UK. E-mail: dmitchis{at}sghms.ac.uk
Colony-forming units of Mycobacterium tuberculosis in sputum were counted at 2-day intervals in 100 patients treated with 22 regimens of isoniazid, rifampin, pyrazinamide, ethambutol, or streptomycin, given alone or in combinations. The exponential fall in colony-forming units was measured by linear regression coefficients of the log counts during the initial 2-day phase of rapid, drug-determined killing and during the subsequent 12 days of much slower sterilizing activity. The regression coefficients during the first 2 days varied significantly according to the drug; the greatest effects in multiple regression analyses were due to isoniazid (p < 0.001) and rifampin (p = 0.027). The rapid kill obtained with isoniazid was unaffected by addition of other drugs, so that a change in activity after adding an unknown drug to isoniazid would not be measurable. In multiple regression analysis of the coefficients during Days 2–14, rifampin and streptomycin had significant effects (p = 0.007 and 0.006, respectively), indicating that both drugs had important sterilizing activity, streptomycin particularly early. Isoniazid and pyrazinamide had no significant effects. In analyses of combined drug regimens only, ethambutol had an effect (p = 0.01) in reverse direction to that of rifampin, suggesting it antagonized the sterilizing activity of other drugs.
Key Words: bactericidal • early bactericidal activity • extended early bactericidal activity • pulmonary tuberculosis • sterilizing
This article has been cited by other articles:
|
|
|
|
 
T. Gumbo, C. S. W. Siyambalapitiyage Dona, C. Meek, and R. Leff
Pharmacokinetics-Pharmacodynamics of Pyrazinamide in a Novel In Vitro Model of Tuberculosis for Sterilizing Effect: a Paradigm for Faster Assessment of New Antituberculosis Drugs
Antimicrob. Agents Chemother.,
August 1, 2009;
53(8):
3197 - 3204.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Goutelle, L. Bourguignon, P. H. Maire, M. Van Guilder, J. E. Conte Jr., and R. W. Jelliffe
Population Modeling and Monte Carlo Simulation Study of the Pharmacokinetics and Antituberculosis Pharmacodynamics of Rifampin in Lungs
Antimicrob. Agents Chemother.,
July 1, 2009;
53(7):
2974 - 2981.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Dietze, D. J. Hadad, B. McGee, L. P. D. Molino, E. L. N. Maciel, C. A. Peloquin, D. F. Johnson, S. M. Debanne, K. Eisenach, W. H. Boom, et al.
Early and Extended Early Bactericidal Activity of Linezolid in Pulmonary Tuberculosis
Am. J. Respir. Crit. Care Med.,
December 1, 2008;
178(11):
1180 - 1185.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Rustomjee, A. H. Diacon, J. Allen, A. Venter, C. Reddy, R. F. Patientia, T. C. P. Mthiyane, T. De Marez, R. van Heeswijk, R. Kerstens, et al.
Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207 in Treatment of Pulmonary Tuberculosis
Antimicrob. Agents Chemother.,
August 1, 2008;
52(8):
2831 - 2835.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Ritchie, A. C. Harrison, R. H. Vaughan, L. Calder, and A. J. Morris
New recommendations for duration of respiratory isolation based on time to detect Mycobacterium tuberculosis in liquid culture
Eur. Respir. J.,
September 1, 2007;
30(3):
501 - 507.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Gumbo, A. Louie, W. Liu, D. Brown, P. G. Ambrose, S. M. Bhavnani, and G. L. Drusano
Isoniazid Bactericidal Activity and Resistance Emergence: Integrating Pharmacodynamics and Pharmacogenomics To Predict Efficacy in Different Ethnic Populations
Antimicrob. Agents Chemother.,
July 1, 2007;
51(7):
2329 - 2336.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. R. Davies, R. Brindle, S. H. Khoo, and L. J. Aarons
Use of nonlinear mixed-effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment.
Antimicrob. Agents Chemother.,
September 1, 2006;
50(9):
3154 - 3156.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. R. Davies, S. H. Khoo, and L. J. Aarons
Optimal sampling strategies for early pharmacodynamic measures in tuberculosis
J. Antimicrob. Chemother.,
September 1, 2006;
58(3):
594 - 600.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. F. Warner and V. Mizrahi
Tuberculosis Chemotherapy: the Influence of Bacillary Stress and Damage Response Pathways on Drug Efficacy
Clin. Microbiol. Rev.,
July 1, 2006;
19(3):
558 - 570.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Ji, S. Lefrancois, J. Robert, A. Chauffour, C. Truffot, and V. Jarlier
In Vitro and In Vivo Activities of Rifampin, Streptomycin, Amikacin, Moxifloxacin, R207910, Linezolid, and PA-824 against Mycobacterium ulcerans.
Antimicrob. Agents Chemother.,
June 1, 2006;
50(6):
1921 - 1926.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. H. Gillespie, R. D. Gosling, L. Uiso, N. E. Sam, E. G. Kanduma, and T. D. McHugh
Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis
J. Antimicrob. Chemother.,
December 1, 2005;
56(6):
1169 - 1171.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Controlling Tuberculosis in the United States
Am. J. Respir. Crit. Care Med.,
November 1, 2005;
172(9):
1169 - 1227.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. A. Sirgel, P. B. Fourie, P. R. Donald, N. Padayatchi, R. Rustomjee, J. Levin, G. Roscigno, J. Norman, H. McIlleron, D. A. Mitchison, et al.
The Early Bactericidal Activities of Rifampin and Rifapentine in Pulmonary Tuberculosis
Am. J. Respir. Crit. Care Med.,
July 1, 2005;
172(1):
128 - 135.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Mitchison
The Diagnosis and Therapy of Tuberculosis During the Past 100 Years
Am. J. Respir. Crit. Care Med.,
April 1, 2005;
171(7):
699 - 706.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. N. Paramasivan, S. Sulochana, G. Kubendiran, P. Venkatesan, and D. A. Mitchison
Bactericidal Action of Gatifloxacin, Rifampin, and Isoniazid on Logarithmic- and Stationary-Phase Cultures of Mycobacterium tuberculosis
Antimicrob. Agents Chemother.,
February 1, 2005;
49(2):
627 - 631.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Janulionis, C. Sofer, H.-Y. Song, and R. S. Wallis
Lack of Activity of Orally Administered Clofazimine against Intracellular Mycobacterium tuberculosis in Whole-Blood Culture
Antimicrob. Agents Chemother.,
August 1, 2004;
48(8):
3133 - 3135.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Mitchison
Fluoroquinolones in the Treatment of Tuberculosis: A Study in Mice
Am. J. Respir. Crit. Care Med.,
February 1, 2004;
169(3):
334 - 335.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Tobin
Tuberculosis, Lung Infections, Interstitial Lung Disease, Social Issues and Journalology in AJRCCM 2003
Am. J. Respir. Crit. Care Med.,
January 15, 2004;
169(2):
288 - 300.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. D. Gosling, L. O. Uiso, N. E. Sam, E. Bongard, E. G. Kanduma, M. Nyindo, R. W. Morris, and S. H. Gillespie
The Bactericidal Activity of Moxifloxacin in Patients with Pulmonary Tuberculosis
Am. J. Respir. Crit. Care Med.,
December 1, 2003;
168(11):
1342 - 1345.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Mitchison
Role of Isoniazid in Once-Weekly Rifapentine Treatment of Pulmonary Tuberculosis
Am. J. Respir. Crit. Care Med.,
May 15, 2003;
167(10):
1298 - 1299.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. J. Burman
The Hunt for the Elusive Surrogate Marker of Sterilizing Activity in Tuberculosis Treatment
Am. J. Respir. Crit. Care Med.,
May 15, 2003;
167(10):
1299 - 1301.
[Full Text]
[PDF]
|
|
|
Copyright © 2003 American Thoracic Society
|
|
|
